Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.44 |
| ▸ | CA7 | P43166 | 12/20 | 0.44 |
| ▸ | CA1 | P00915 | 11/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 10/20 | 0.44 |
| ▸ | CA12 | O43570 | 10/20 | 0.44 |
| ▸ | CA4 | P22748 | 9/20 | 0.44 |
| ▸ | CA6 | P23280 | 9/20 | 0.44 |
| ▸ | CA9 | Q16790 | 9/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 9/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 9/20 | 0.44 |
| ▸ | CA3 | P07451 | 7/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11549637 | 0.85 | KDM4E (0.50) | CA2CA7CA1CA13CA12 | |
| SCHEMBL11845199 | 0.83 | KDM4E (0.41) | CA2CA7CA1CA13CA12 | |
| SCHEMBL11800566 | 0.82 | CA2 (0.45) | CA2CA1CA12CA9CDC25B | |
| SCHEMBL2879281 | 0.80 | MAPT (0.48) | CA2CA7CA1CA13CA12 | |
| SCHEMBL11849523 | 0.79 | CNR2 (0.46) | CA2CA7CA1CA13CA12 | |
| SCHEMBL11370788 | 0.79 | CA2 (0.42) | CA2CA7CA1CA13CA12 | |
| SCHEMBL10281400 | 0.78 | KDM4E (0.61) | CA2CA7CA1CA13CA12 | |
| SCHEMBL11788977 | 0.78 | CISD1 (0.53) | CA2CA7CA1CA13CA12 | |
| SCHEMBL11543455 | 0.77 | KDM4E (0.60) | CA2CA7CA1CA13CA12 | |
| Hydrochloric Acid SCHEMBL11540279 | 0.77 | CA2 (0.40) | CA2CA7CA1CA13CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9682928-B2 | Bumetanide analogs, compositions and methods of use | NEUROPRO THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS INC. | 2015-03-19 | — | — | US | disclosed |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2010085352-A2 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| US-3985777-A | Sulphamyl-benzoic acid derivatives | LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB (DK) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CA2 471/4885CA7 617/4885CA1 1022/4885 |
| US-20190151263-A1 | BUMETANIDE ANALGOS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A11, SLC6A13 | CA2 388/4885CA7 370/4885CA1 701/4885 |
| US-20120004225-A1 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | ABCG2, ABCB1, TRPV1 | CA2 1572/4885CA7 2723/4885CA1 1755/4885 |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CA2 1422/4885CA7 1507/4885CA1 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.